


LivaNova

Health innovation that matters

LivaNova Intent to Acquire TandemLife

February 14, 2018



Safe Harbor Statement – Forward Looking Statements

Certain statements in this presentation, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-4 and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova.

The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this presentation to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this presentation.

All numbers may be rounded for presentation purposes.

Safe Harbor Statement – Intellectual Property

In this presentation, “LivaNova,” “the Company,” “we,” “us” and “our” refer to LivaNova PLC and its consolidated subsidiaries.

This report may contain references to our proprietary intellectual property, including among others:

- Trademarks for our VNS therapy systems, the VNS Therapy® System, the VITARIA® System and our proprietary pulse generator products: Model 102 (Pulse®), Model 102R (Pulse Duo®), Model 103 (Demipulse®), Model 104 (Demipulse Duo®), Model 105 (AspireHC®), Model 106 (AspireSR®) and Model 1000 (SenTiva™).
- Trademarks for our oxygenator product systems: Inspire™, Heartlink™ and Connect™.
- Trademarks for our line of surgical tissue and mechanical valve replacements and repair products: Mitroflow™, Crown PRT™, Solo Smart™, Perceval™, Top Hat™, Reduced Series Aortic Valves™, Carbomedics Carbo-Seal™, Carbo-Seal Valsalva™, Carbomedics Standard™, Orbis™ and Optiform™, and Mitral valve repair products: Memo 3D™, Memo 3D ReChord™, AnnuloFlo™ and AnnuloFlex™.
- Trademarks for our implantable cardiac pacemakers and associated services: REPLY 200™, ESPRIT™, KORA100™, KORA250™, SafeR™, the REPLY CRT-P™, the remedé® System.

These trademarks and tradenames are the property of LivaNova or the property of our consolidated subsidiaries and are protected under applicable intellectual property laws. Solely for convenience, our trademarks and tradenames referred to in this presentation may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames.

We are a \$1.2B focused medical innovator*

Improving quality of patients' lives

Strong leadership position in Neuromodulation and Cardiac Surgery

Targeting underserved and high-growth market segments



Our portfolios are focused on “Head & Heart”

	NEUROMODULATION	CARDIAC SURGERY	
		CARDIOPULMONARY	HEART VALVES
	Creator, leader of VNS Therapy	Market-leading positions	Only sutureless valve on the market
Global Market (2016)*	\$4.1B	\$3.0B	\$1.7B
Market Growth	Low-double-digit	Low-single-digit	Low-single-digit
Sales (2016)*	\$350M	\$475M	\$140M
Sales through Q317*	\$275M	\$355M	\$103M
Disease State	Drug-resistant epilepsy Treatment-resistant depression (TRD) Obstructive sleep apnea	Heart valve disease Coronary disease Congenital heart defect Heart failure	
Customers	Neurologists Epileptologists Psychiatrists Neurosurgeons ENT Specialists	Perfusionists Intensivists Cardiac Surgeons Cardiologists Interventional Cardiologists	

TandemLife overview – “Life support simplified”

- Founded in 1996 as CardiacAssist, Inc.
- Began selling product under “TandemLife” in 2016
- Focused on Advanced Percutaneous Cardiopulmonary Support Solutions
 - **ExtraCorporeal Life Support (ECLS)**
 - **Percutaneous Mechanical Circulatory Support (pMCS)**
- TandemLife products used in >5,000 patient cases
- Focused on products that are simple enough to setup and deploy across a broad group of hospitals
- Headquartered in Pittsburgh with ~70 employees
- U.S. direct sales force of ~20



TandemLife solutions are complementary to LIVN's strong offerings in cardiac surgery

CARDIOPULMONARY SUPPORT

TANDEM LIFE

Veno-Arterial ECLS

- Veno – Arterial bypass

Components:

- Pump
 - Oxygenator
 - Femoral arterial cannula
 - Femoral venous cannula
- Available since 2017



RESPIRATORY SUPPORT

TANDEM LUNG

Veno-Venous ECLS

- Veno – Venous bypass

Components:

- Pump
 - Oxygenator
 - Dual lumen venous cannula
- Available since 2016



LEFT HEART SUPPORT


TANDEM HEART

Left Heart Support

- Left Atrium – Femoral Artery bypass

Components:

- Pump
 - Femoral arterial cannula
 - Femoral venous transseptal cannula
- Available since 2002



RIGHT HEART SUPPORT

PROTEK DUO

Right Heart Support

- Right Atrium – Pulmonary Artery bypass

Components:


- Pump
 - Dual lumen venous cannula
- Available since 2014



Double-digit top line growth; significant opportunity for expansion

- 45% sales growth from 2016 to 2017*
- 95% of sales in the U.S.
- Versatile platform built around common pump and controller
- Next-gen pump and controller will be a step-forward in ease of use
- **Near-term:** focus on large and growing ECLS and pMCS segments in the U.S.
- **Mid-term:** launch next-generation pump and controller and implement geographic expansion strategy
- **Long-term:** advance into broader cardiopulmonary applications

Historical revenues (\$M)



* Numbers are rounded for presentation purposes

** 2017 preliminary unaudited financials

Product Line	Pump	Oxygenator	Cannulae
TandemLife	●	●	●
TandemLung	●	●	●
ProtekDuo	●		●
TandemHeart	●		●

The deal makes strong strategic sense

Opportunity



- Aligned with strategy of finding acquisitions complementary to our existing portfolio
- \$1B largely under-penetrated segment
- TandemLife has system solutions for all applications
- Significant upside potential of increased share, geographic expansion and penetration into emerging applications

Portfolio



- The most versatile platform built around a common pump & controller
- Strong acceptance of new products launched in the past 3 years
- Next generation pump and controller in development

Strategic fit



- Immediate commercial synergies: perfusionists and cardiac surgeons
- Significant potential to leverage OUS channels and expand geographically
- Building interventional cardiologist call point for Caisson

Financial



- \$200M up front payment; \$50M based on regulatory milestones
- Modestly accretive in 2018; generating cash
- Expected to close in 1H18, after completion of closing conditions

Accessing a \$1B temporary support solutions opportunity, while advancing the standard of care

	Mechanical Circulatory Support (MCS)			Respiratory Support		
	Standard-of-Care	Advanced		Standard-of-Care	Advanced	
Devices and Techniques	Intra-Aortic Balloon Pump (IABP)	Right and Left Heart Support	Veno-Arterial ECLS	Surgical LVADs	Mechanical Ventilation (MV)	Veno-Venous ECLS
Estimated Segment Value	\$250M	\$600M	\$160M	\$1B	\$300M	\$240M
Key Players	Maquet Teleflex	Abiomed TandemLife	Maquet TandemLife	Abbott Medtronic	Multiple Players	Maquet TandemLife

POTENTIAL APPLICATIONS:

Note: Pivotal data does not yet confirm definitive claims

Cardiac

- Cardiogenic shock
- High risk percutaneous coronary interventions
- Right ventricle failure

Cardiopulmonary

- Post cardiopulmonary bypass
- Cardiac arrest

Pulmonary

- Acute respiratory distress syndrome
- Acute exacerbation of chronic obstructive pulmonary disease

Driving shareholder value creation

OPPORTUNITY

- Near-term focus on large and growing ECLS and pMCS segments in the U.S.
- Mid-term focus on geographic expansion
- Long-term focus on advancing into broader cardiopulmonary applications

SOLUTIONS

- Versatile platforms built around common pump and controller
- Next-generation pump and controller in development

FINANCIALS

- Strong double-digit top line growth
- Modestly accretive in 2018
- Immediate cash generation

LivaNova

Health innovation that matters